324 related articles for article (PubMed ID: 10522044)
1. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.
Yamaguchi K; Chijiiwa K; Noshiro H; Torata N; Kinoshita M; Tanaka M
Hepatogastroenterology; 1999; 46(28):2575-81. PubMed ID: 10522044
[TBL] [Abstract][Full Text] [Related]
2. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
[TBL] [Abstract][Full Text] [Related]
4. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
Mueller J; Gansauge S; Mattfeldt T
Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
[TBL] [Abstract][Full Text] [Related]
5. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
Caldas C; Hahn SA; Hruban RH; Redston MS; Yeo CJ; Kern SE
Cancer Res; 1994 Jul; 54(13):3568-73. PubMed ID: 8012983
[TBL] [Abstract][Full Text] [Related]
6. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
[TBL] [Abstract][Full Text] [Related]
7. [Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas].
Daus H; Trümper L; Bürger B; Jacobs G; Kriener S; von Blohn G; Zeitz M; Pfreundschuh M
Dtsch Med Wochenschr; 1995 Jun; 120(23):821-5. PubMed ID: 7781522
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice.
Uehara H; Nakaizumi A; Baba M; Iishi H; Tatsuta M; Kitamura T; Ohigashi H; Ishikawa O; Takenaka A; Ishiguro S
Am J Gastroenterol; 1996 Aug; 91(8):1616-21. PubMed ID: 8759672
[TBL] [Abstract][Full Text] [Related]
9. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.
Pellegata NS; Sessa F; Renault B; Bonato M; Leone BE; Solcia E; Ranzani GN
Cancer Res; 1994 Mar; 54(6):1556-60. PubMed ID: 8137263
[TBL] [Abstract][Full Text] [Related]
10. Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas.
Kimura W; Zhao B; Futakawa N; Muto T; Makuuchi M
Hepatogastroenterology; 1999; 46(25):532-9. PubMed ID: 10228857
[TBL] [Abstract][Full Text] [Related]
11. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
12. Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients.
Dong M; Nio Y; Tamura K; Song MM; Guo KJ; Guo RX; Dong YT
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):279-84. PubMed ID: 10750666
[TBL] [Abstract][Full Text] [Related]
13. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations.
Gansauge S; Schmid RM; Muller J; Adler G; Mattfeldt T; Beger HG
Br J Surg; 1998 Mar; 85(3):337-40. PubMed ID: 9529487
[TBL] [Abstract][Full Text] [Related]
15. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma.
Yamaguchi K; Nakano K; Nagai E; Chijiiwa K; Kinoshita M; Ohta M; Tanaka M
Hepatogastroenterology; 2005; 52(63):713-8. PubMed ID: 15966189
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations in adenoma-carcinoma sequencing of intraductal papillary-mucinous neoplasm of the pancreas.
Nakata B; Yashiro M; Nishioka N; Aya M; Yamada S; Takenaka C; Ohira M; Ishikawa T; Nishino H; Wakasa K; Hirakawa K
Int J Oncol; 2002 Nov; 21(5):1067-72. PubMed ID: 12370756
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation.
Arvanitakis M; Van Laethem JL; Parma J; De Maertelaer V; Delhaye M; Devière J
Endoscopy; 2004 Jun; 36(6):535-42. PubMed ID: 15202051
[TBL] [Abstract][Full Text] [Related]
18. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis.
Löhr M; Müller P; Mora J; Brinkmann B; Ostwald C; Farré A; Lluis F; Adam U; Stubbe J; Plath F; Nizze H; Hopt UT; Barten M; Capellá G; Liebe S
Gastrointest Endosc; 2001 Jun; 53(7):734-43. PubMed ID: 11375580
[TBL] [Abstract][Full Text] [Related]
19. [Point mutation at codon 12 of c-Ki-ras oncogene in human pancreatic neoplasms and normal human pancreas tissue].
Cui Q; Wang Z; Chen J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Jun; 16(3):201-5. PubMed ID: 7805165
[TBL] [Abstract][Full Text] [Related]
20. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival.
Sessa F; Bonato M; Bisoni D; Ranzani GN; Capella C
Eur J Histochem; 1998; 42 Spec No():67-76. PubMed ID: 10076772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
